Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by Barewoodon May 24, 2018 1:40pm
248 Views
Post# 28076348

RE:RE:RE:The split is on the table

RE:RE:RE:The split is on the tableThe major point here is, and if you look through and or listen to the updates provided by the Company, if Neovasc does not meet the NASDAQ's minimum pps of $1.00, the Company stands the risk of being delisted, which means Neovasc will not have access to major institutional investors. The Goal hear is to bring it two key products to the U.S.. Read the following and you'll see: News Release
<< Previous
Bullboard Posts
Next >>